Company: LENZ
Filing Date: 2025-04-14
Form Type: 424B3
Source: 0001628280-25-017694
Chunk: 12

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-14
Form: 424B3
Chunk 12
---
 competitive position and the success of competing therapies that are or may become available;

• the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of LNZ100;

• the need to hire additional personnel and our ability to attract and retain such personnel;

• our plans relating to the further development and manufacturing of LNZ100 and any future product candidates;

• the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise;

• the rate and degree of market acceptance and clinical utility of LNZ100 and any other product candidates we may develop;

<div align='center'>7</div>

• the impact of existing laws and regulations and regulatory developments in the United States and other jurisdictions;

• our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering LNZ100, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;

• our continued reliance on third parties to conduct any additional clinical trials of LNZ100 or any future product candidates, and for the manufacture of our product candidates for any such trials;

• the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

• our financial performance;

• our ability to recognize the anticipated benefits of the Merger;

• the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;

• our expectations regarding the period during which we will remain an emerging growth company under the JOBS Act;

• our anticipated use of our existing resources and the proceeds from the Merger; and

• the risks and uncertainties described under the heading “Risk Factors” and in our current and periodic reports, and other filings, filed from time to time with the SEC that are incorporated by reference into this prospectus.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks.

The forward-looking statements made in this prospectus relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this prospectus to reflect events or circumstances after the date of this prospectus or to reflect new information or the occurrence of unanticipated events